ÂÜÀòÂÒÂ×

Amanda joins from Axsome Therapeutics, where she led the clinical development of the first and only oral NMDA receptor antagonist approved for treating major depressive disorder in adults (Auvelity®). Prior to joining Axsome, she had varying roles of increasing responsibility in clinical research & development at Salix Pharmaceuticals and United Therapeutics. Amanda earned her Doctor of Pharmacy degree and completed a post-doctoral fellowship in clinical research and drug development at UNC-Chapel Hill Eshelman School of Pharmacy. She earned her B.S. in Biochemistry from Florida State University.